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Abstract Bone morphogenetic proteins (BMPs) transdifferenti-
ate C2C12 cells from the myogenic to the osteogenic lineage. In
this work we examine the role of the phosphatidylinositol 3-
kinase/p70 S6 kinase (PI3K/p70 S6K) and p38 mitogen-activated
protein kinase (p38 MAPK) cascades in the osteogenic effects of
BMP-2. BMP-2 stimulated both cascades transiently (maximal
at 1 h and decreasing thereafter). In contrast, BMP-2 had no
effect on p42/p44 MAPK (Erks) stimulation. We also analyzed
the effects of selective inhibitors of these pathways on the
expression of osteogenic markers. Inhibitors of p38 MAPK
(SB203580) or the PI3K/p70 S6K pathway (Ly294002 and
rapamycin) not only fail to block the osteoblast phenotype
induced by BMP-2, measured as induction of Cbfa1 expression
and transcriptional activity, but also potentiate the effect of
BMP-2 on late osteoblast markers, such as alkaline phosphatase
activity and osteocalcin expression. These data suggest that, in
contrast to their positive effect on myogenic differentiation,
PI3K/p70 S6K and p38 MAPK cascades have a negative role in
osteoblast differentiation. ß 2002 Published by Elsevier Sci-
ence B.V. on behalf of the Federation of European Biochemical
Societies.
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1. Introduction
Mesenchymal precursors can di¡erentiate to di¡erent cellu-
lar types, such as adipocytes, myoblasts, ¢broblasts or osteo-
blasts. The fate of a cell depends on mutually exclusive extra-
cellular signalling factors. For example, signals that induce the
osteoblast phenotype repress myogenic di¡erentiation in vitro
[1,2] and induce bone formation after implantation in intra-
muscular sites in vivo [3]. The fate of the mesenchymal pre-
cursors seems to rely on the expression of ‘master’ genes,
MyoD/Myf5/myogenin for myoblasts, PPARQ2 and C/EBPs
for adipocytes or Cbfa1 for osteoblasts [4].
Each di¡erentiation program is ultimately controlled by
signals and regulatory pathways that activate a speci¢c set
of transcription factors. Among them, bone morphogenetic
proteins (BMPs), which belong to the transforming growth
factor-L (TGFL) superfamily of signalling molecules [5] induce
osteoblast di¡erentiation in vitro and in vivo, bone regener-
ation and ectopic bone formation [6]. BMPs also determine
crucial steps in embryogenesis, acting as morphogens [5].
BMPs signal through a heterodimeric complex of type I and
type II serine/threonine kinase receptors [7,8]. This complex
phosphorylates and activates the Smad family of proteins,
which transduce the signal to the nucleus [7,9,10]. The
BMP-activated Smads are Smad1 and 5, which, upon phos-
phorylation by the receptor, interact with Smad4 and trans-
locate to the nucleus where they stimulate BMP-induced
genes. Other mediators of signals of the TGFL superfamily
members involve kinase cascades such as TAK1 and JNK:
TAK functions as a mediator of the MKK6-p38 mitogen-ac-
tivated protein kinase (MAPK) and MKK7-JNK stimulation
and mediates BMP signals in early development in Xenopus,
whereas JNK mediates activation of ¢bronectin synthesis
from TGFL receptors [11,12].
In addition to morphogenetic signals that induce the ex-
pression of tissue-speci¢c regulatory genes, other signal trans-
duction cascades contribute to cellular commitment. Phospha-
tidylinositol 3-kinase (PI3K) and p38 MAPK cascades
promote myogenic di¡erentiation [13^15]; p38 MAPK activ-
ity is also required for chondrogenesis, adipogenesis or neuro-
nal di¡erentiation (reviewed in [16]) and p42/p44 MAPK (or
Erks) is required for osteoblastic and neuronal di¡erentiation
[1,17^19]. These di¡erentiation programs are initiated by ei-
ther transcriptional or posttranscriptional activation of cell
type-speci¢c transcription factors, as well as the promotion
of additional commitment networks. For instance, p38 phos-
phorylates and activates C/EBPL during adipogenesis or
MEF2C during myogenesis [16], whereas Erks activate
Cbfa1 [20]. However, there is no information on the contri-
bution of PI3K/p70 S6K or p38 MAPK signalling cascades to
the induction of the osteoblast phenotype. In the present
study we show that, in contrast to the myogenic or adipogenic
di¡erentiation programs, inhibitors of both cascades do not
block, but rather potentiate the osteoblast di¡erentiation of
C2C12 cells induced by BMP-2.
2. Materials and methods
2.1. Materials
Human recombinant BMP-2 was obtained from Genetics Institute,
SB203580 from Sigma, LY294002 from Alexis and rapamycin from
BioMol. Cell culture media, fetal bovine serum (FBS), glutamine and
antibiotics were obtained from Gibco BRL. Other reagents were of
analytical grade or molecular biology grade and purchased from Sig-
ma or Roche.
2.2. Id183 plasmid
The promoter region of the human Id1 gene (31370 to +86) was
ampli¢ed by polymerase chain reaction (PCR) and subcloned into
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pBluescript vector, sequenced and further subcloned into the promo-
terless luciferase reporter vector pGL2-basic (pId1lux) (Promega,
Madison, WI, USA). Sequences of the primers used for the PCR
were 5P-GACAAACTCTTCATCAGAGCTCGCT-3P (upstream) and
5P-CATGATTCTTGTCGACTGGCTGAAA-3P (downstream). 5P-
Deletions were generated through partial and total SmaI digestions
using the sites present in the vector and the promoter region. The
pId170 reporter construct (3170 to +86) corresponds to the minimal
promoter and includes the endogenous TATA box. The 183 bp en-
hancer fragment identi¢ed (corresponding to the 31046 to 3863 bp)
was subcloned into SmaI sites of pId170 generating the pId183 con-
struct.
2.3. Cell culture, transfections and luciferase assay
C2C12 mouse cells were cultured in Dulbecco’s modi¢ed Eagle’s
medium (DMEM) containing 20% inactivated FBS, 50 U/ml penicillin
and 50 Wg/ml streptomycin sulfate. Con£uent cells were di¡erentiated
in DMEM containing 2% horse serum in the presence or the absence
of the indicated concentrations of BMP-2 and the inhibitors. The
results obtained were the same independently whether the inhibitors
were added once or changed every 24 h.
C2C12 cells were transiently transfected after addition of di¡eren-
tiation medium with the osteoblast-speci¢c region of mouse osteocal-
cin promoter fused to a luciferase reporter (pOG2-147-Luc) [21] or the
Id183 enhancer construct, and a L-galactosidase vector using Fugene
(Roche). Luciferase assays were carried out using the Luciferase Assay
System (Promega) 16 h (Id183) or 3 days (osteocalcin promoter) after
transfection. L-Galactosidase activity was measured using a Lumines-
cent L-galactosidase Detection kit II (Clontech).
2.4. Western blot analysis
Cells were washed twice in cold phosphate-bu¡ered saline (PBS)
and lysed in Triton X-100 lysis bu¡er (50 mM Tris^HCl (pH 7.5),
100 mM NaCl, 50 mM NaF, 5 mM EDTA, 40 mM L-glycerophos-
phate, 200 WM sodium orthovanadate, 100 WM phenylmethylsulfonyl
£uoride, 1 WM pepstatin A, 1 Wg/ml leupeptin, 4 Wg/ml aprotinin, 1%
Triton X-100) for 15 min at 4‡C. Insoluble material was removed by
centrifugation at 12 000Ug for 5 min at 4‡. Proteins were separated by
sodium dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^
PAGE) and electrophoretically transferred to Immobilon-P mem-
branes (Millipore) in 25 mM Tris^HCl, 0.19 M glycine and 20%
ethanol. Membranes were blocked in TBS (50 mM Tris, pH 7.4,
150 mM NaCl) containing 5% non-fat dry milk for 1 h at 37‡C.
The blots were incubated with polyclonal anti-phospho-(Ser473)-Akt
antibody (New England Biolabs), polyclonal anti-Akt antibody (New
England Biolabs), polyclonal anti-p42 MAPK [22], monoclonal anti-
phospho-Erk1/2 antibody (Sigma), polyclonal anti-phospho-p70 S6K
antibody (New England Biolabs), polyclonal anti-phospho-p38
MAPK antibody (Promega), polyclonal anti-p38 MAPK antibody
(Upstate Biotechnology), polyclonal anti-p21Waf1=Cip1 antibody (Santa
Cruz), polyclonal anti-phospho-Smad1 (Upstate Biotechnology) and
polyclonal anti-Cbfa1 antibody (Santa Cruz) in blocking solution
overnight at 4‡C. After washing in TBS, 0.1% Tween 20, blots were
incubated with anti-rabbit Ig (Amersham Pharmacia), anti-mouse Ig
(Amersham Pharmacia) or anti-goat Ig (Dako) horseradish peroxi-
dase linked antibodies in blocking solution for 1 h and developed
with an enhanced chemiluminescence system (Amersham Pharmacia).
2.5. Northern blot
Total RNA from cells was extracted using the phenol/chloroform
method [23]. 20 Wg of RNA were denatured at 65‡C in the presence of
formamide, formaldehyde and ethidium bromide. RNA was separated
on a 1.5% agarose/formaldehyde gel and blotted on Hybond N+
¢lters (Amersham Pharmacia). Blots were hybridized to the mouse
osteocalcin cDNA (a generous gift from Dr. G. Karsenty, Baylor
College of Medicine, Houston, TX, USA) or rat GAPDH cDNA
labelled with [K-32P]dCTP (Amersham Pharmacia), and incubated
overnight at 42‡C in 50% formamide, 5U Denhardt’s (1U Denhardt’s
is 0.02% Ficoll, 0.02% polyvinylpyrrolidone and 0.02% bovine serum
albumin) 0.1% SDS, 5U SSPE (1U SSPE is 10 mM NaH2PO4, pH
7.4, 150 mM NaCl and 1 mM EDTA), 5% dextran sulfate, and 200
Wg/ml denatured salmon sperm DNA. After hybridization, mem-
branes were washed in 0.1U SSC (1U SSC is 15 mM sodium citrate,
pH 7 and 150 mM NaCl)^0.1% SDS at 50‡C for 50 min. The blots
were exposed to Kodak ¢lms.
2.6. Alkaline phosphatase activity
Cells were washed twice in PBS and lysed on 20 mM Tris^HCl, pH
8, 150 mM NaCl, 0.2% NP40 and 10% glycerol. Cell lysates (25 Wg)
were incubated in a bu¡er containing 0.1 M glycylglycine, 10 mM
MgCl2, 1 mM ZnSO4, 10 mM p-nitrophenyl phosphate, pH 9.5 at
37‡C for 2 h. The reaction was stopped with 0.5 N NaOH and ab-
sorbance was measured at 405 nm.
3. Results
3.1. Activation of di¡erent protein kinase cascades during
BMP-2-induced osteoblast di¡erentiation of C2C12 cells
As previously described, C2C12 cells with a limited supply
of growth factors (2% horse serum) di¡erentiate into myo-
blasts, which later fuse into multinucleated myotubes (Fig.
2). Treatment with BMP-2 completely blocked myoblast dif-
ferentiation (Fig. 2, [24,25]). We analyzed the activation of
p70 S6K, Akt, p38 and p42/p44 MAPKs during di¡erentia-
tion of C2C12 cells in the presence or the absence of BMP-2.
Depletion of growth factors caused a progressive drop in
PI3K (measured by phosphorylation of Akt, a downstream
target), p70 S6K and p42/p44 MAPK activities (Fig. 1), until
Fig. 1. E¡ect of BMP-2 stimulation on p70 S6K, Akt, p42/p44
MAPK and p38 MAPK activities. A: Con£uent C2C12 cells were
incubated (for the periods of time indicated) in DMEM supple-
mented with 2% horse serum in the absence or in the presence of
10 nM BMP-2. Cells were lysed and Western blot was performed
using anti-active p70 S6K (pp70 S6K), anti-active Akt (pAkt), total
Akt (Akt), anti-active p42/p44 MAPK (pp42/p44 MAPK), total p42
MAPK (p42 MAPK), anti-active p38 MAPK (pp38) and total p38
MAPK (p38) antibodies. A representative Western blot is shown.
B: Quanti¢cation of data shown in (A). Results were normalized by
the level of p42 MAPK. Values represent the mean of three inde-
pendent experiments and are expressed relative to their respective
control in the absence of BMP-2.
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the complete inactivation of these signaling pathways after
24 h. In contrast, p38 MAPK activity increased slightly after
4 h in di¡erentiation medium, peaked at 8 h and returned to
basal levels after 24 h. Addition of BMP-2 transiently stimu-
lated p38 MAPK at 15 min and activation was maximal at
1 h. BMP-2 also stimulated Akt and p70 S6K, but only
after incubation for at least 1 h. The stimulation was main-
tained until 4 h and progressively normalized after 8 h. No
e¡ect of BMP-2 was observed thereafter for up to 3 days, or
on p42/p44 MAPK (Fig. 1) or JNK activities (data not
shown).
3.2. E¡ect of inhibitors of PI3K/p70 S6K and p38 MAPK
cascades on the osteoblast di¡erentiation of C2C12 cells
induced by BMP-2
To examine the role of PI3K, p70 S6K and p38 MAPK
activities in the induction of osteogenic di¡erentiation by
BMP-2, C2C12 cells were incubated in di¡erentiation medium
in the presence or the absence of BMP-2 with either 15 WM
Ly294002, a speci¢c inhibitor of PI3K activity, 10 nM rapa-
mycin, a speci¢c inhibitor of p70 S6K activity, or 10 WM
SB203580, a speci¢c inhibitor of p38 MAPK. As described
before [14], all these inhibitors blocked the induction of the
skeletal muscle phenotype visualized as myotube formation
(Fig. 2A) or the induction of the p21Waf1=Cip1 (Fig. 2B), where-
as the presence of concentrations as low as 2 nM BMP-2
Fig. 2. BMP-2, Ly294002, rapamycin and SB203580 block skeletal muscle di¡erentiation. A: Con£uent C2C12 cells were depleted of growth
factors and incubated in a medium containing 2% horse serum for 3 days in the absence or the presence of 2 nM BMP-2, 15 WM Ly294002,
10 nM rapamycin or 15 WM SB203580. Cells were examined by phase-contrast microscopy and photographed. Magni¢cation: 100U. B: Con-
£uent C2C12 cells were depleted or not (20%) of growth factors and incubated in a medium containing 2% horse serum for 3 days in the ab-
sence (2%) or the presence of 2 nM BMP-2, 15 WM Ly294002 (Ly), 10 nM rapamycin (R) or 15 WM SB203580 (SB). After lysis 50 Wg of pro-
tein was separated on an SDS^12% polyacrylamide gel, and p21Waf1=Cip1or p42 MAPK (as protein loading control) were immunodetected with
speci¢c antibodies. A representative Western blot is shown.
Fig. 3. PI3K, p70 S6K or p38 MAPK inhibition does not a¡ect
BMP-2 signaling cascade. Quiescent C2C12 cells were preincubated
for 15 min in the absence (3) or the presence of 15 WM Ly294002
(Ly), 10 nM rapamycin (R) or 15 WM SB203580 (SB). After this
time, cells were stimulated for 30 min with 2 nM BMP-2 or 10%
FCS or were left unstimulated (0). Cells were lysed, and phospho-
Smad1 (pSmad1), phospho-p70 S6K (pp70 S6K), phospho-Akt
(pAkt), phospho-p42/p44 MAPK (pp42/p44 MAPK) and p42
MAPK were immunodetected as described. A Western blot repre-
sentative of three di¡erent experiments is shown.
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completely blocked myotube formation, with no di¡erences in
the presence of the various inhibitors.
In order to determine whether the inhibition of these signal-
ing pathways in£uences the BMP-2 signal transduction cas-
cade, we measured the e¡ect of treatment with Ly294002,
rapamycin and SB203580 on the stimulation by BMP-2 of
the phosphorylation of Smad1. The addition of all these in-
hibitors did not alter the BMP-2-induced phosphorylation of
Smad1 (Fig. 3), whereas preincubation with Ly294002 specif-
ically prevented PI3K activation by fetal calf serum (FCS;
measured by the phosphorylation state of two downstream
targets, Akt and p70 S6K) and incubation with rapamycin
blocked the p70 S6K stimulation (Fig. 3). The speci¢city of
this inhibition was con¢rmed by the absence of p42/p44
MAPK inhibition in response to Ly294002 or rapamycin.
Moreover, we have measured the e¡ect of all these inhibitors
on the stimulation by BMP-2 of the promoter of Id1, an
immediate early gene induced by BMP-2. We have identi¢ed
a BMP-2 responsive region in the Id1 promoter which is suf-
¢cient to confer BMP-2 responsiveness (Teresa Lo¤pez-Rovira
et al., JBC manuscript in press). The addition of all these
inhibitors did not modify the transcriptional responses on Id
promoter by BMP-2 (3.6 þ 0.7-fold induction by BMP-2
alone, 4.1 þ 1.1-fold induction by BMP-2 in the presence of
15 WM Ly294002, 4.6 þ 1.2-fold in the presence of 10 mM
rapamycin and 4.8 þ 0.7-fold in the presence of 10 WM
SB203580). All these results indicate a lack of e¡ect of the
p38 MAPK and PI3K/p70 S6K pathways on the signaling
cascade induced by BMP-2.
Next, we have determined the requirement of these signal-
ling pathways for osteoblast di¡erentiation, we ¢rst studied
the induction of an earliest marker of the osteoblast pheno-
type, the transcription factor Cbfa1 [26]. This marker, immu-
nodetected as a double band [27], was present at low levels on
C2C12 cells after 3 days in di¡erentiation media ([4], Fig. 4A).
Incubation with BMP-2 induced Cbfa1 at 24 h (data not
shown) and at 3 days (Fig. 4A). More importantly, Cbfa1
was similarly induced by BMP-2 in the presence of the di¡er-
ent inhibitors, Ly294002, rapamycin and SB203580. Since
p42/p44 MAPK activity phosphorylates and regulates Cbfa1
activity [20] we examined whether Cbfa1 transcriptional activ-
ity was a¡ected by PI3K/p70 S6K or p38 MAPK inhibition.
With this objective we measured the activity of a reporter
construct containing the minimal osteoblast-speci¢c enhancer
of the osteocalcin promoter that contains a Cbfa1-responsive
region [21,26]. As shown in Fig. 4B, after 3 days in di¡er-
entiation media, BMP-2 induced a 2.5-fold increase in the
osteocalcin reporter activity. Addition of the di¡erent inhib-
itors did not signi¢cantly a¡ect the basal reporter activity or
the BMP-2 fold induction (2.5-fold increase without inhibi-
tors, 3.1-fold in the presence of Ly294002, 2.8-fold in the
presence of rapamycin, and 2.7-fold in the presence of
SB203580). These results indicate that, in contrast with their
requirement for skeletal muscle di¡erentiation, PI3K/p70 S6K
cascade and p38 MAPK activation are not essential for BMP-
2 induction of Cbfa1 gene expression and transcriptional ac-
tivity.
Finally, we analyzed the e¡ects of the inhibitors of the
Fig. 4. PI3K, p70 S6K or p38 MAPK inhibition does not a¡ect
Cbfa1 induction and transcriptional activity. A: Con£uent C2C12
cells were allowed to di¡erentiate in the absence (0) or in the pres-
ence of 2 or 10 nM BMP-2 alone or in the presence of 15 WM
Ly294002 (Ly), 10 nM rapamycin (Rapa) or 15 WM SB203580 (SB)
for three days. After lysis 30 Wg of protein was separated on an
SDS^10% polyacrylamide gel, and Cbfa1 or p42 MAPK (as protein
loading control) were immunodetected with speci¢c antibodies. A
representative Western blot is shown. B: C2C12 cells depleted of
growth factors were transiently transfected with osteocalcin-lucifer-
ase reporter and L-galactosidase vector, and incubated for 3 days in
the absence (2%) or the presence of 2 nM BMP-2 alone or in the
presence of 15 WM Ly294002 (Ly), 10 nM rapamycin (Rapa) or 15
WM SB203580 (SB). After this time cells were harvested and lucifer-
ase and L-galactosidase activities were measured. The results are the
mean þ S.E.M. of three independent experiments and are expressed
as relative luciferase/L-galactosidase activities.
Fig. 5. PI3K, p70 S6K or p38 MAPK inhibition does not block but
stimulates alkaline phosphatase activity. Con£uent C2C12 cells were
depleted of growth factors and incubated in a medium containing
2% horse serum for 3 days in the absence (2%) or the presence of
2 nM BMP-2, 15 WM Ly294002 (Ly), 10 nM rapamycin (Rapa) or
15 WM SB203580 (SB). After this time cells were lysed and alkaline
phosphatase was determined as described in Section 2. Data are the
mean þ S.E.M. of three independent experiments.
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PI3K/p70 S6K and p38 MAPK cascades on markers of osteo-
blast terminal di¡erentiation. First, treatment with BMP-2
induced a ¢ve-fold increase in alkaline phosphatase activity
after 3 days (Fig. 5). Control treatments with rapamycin or
SB203580 did not signi¢cantly a¡ect the basal alkaline phos-
phatase activity, whereas Ly294002 slightly increased basal
activity. More importantly, the inhibitors not only failed to
block the BMP-stimulation but rather potentiated its e¡ect,
with a 17-fold increase in the presence of Ly294002, a 13-fold
increase in the presence of rapamycin, and a nine-fold increase
in the presence of SB203580. Finally, we studied the expres-
sion of the later osteoblast marker osteocalcin, by measuring
its mRNA by northern analysis. As shown in Fig. 6, treatment
with BMP-2 for 6 days induced osteocalcin mRNA. Incuba-
tion of cells in the presence of Ly294002 for 6 days had a
deleterious e¡ect on cell viability, with a strong decrease in
cell number and mRNA levels, as shown by basal GAPDH
expression (Fig. 6). However in the presence of BMP-2 and
Ly294002, osteocalcin mRNA was similarly induced to con-
trol cells. Incubation of C2C12 cells in 2% horse serum in the
presence of rapamycin or SB203580 increased the basal levels
of osteocalcin, while the capacity of BMP-2 to induce osteo-
calcin mRNA was also maintained.
4. Discussion
Although activation of PI3K/p70 S6K and MAPK signal-
ling cascades has been associated with many di¡erent physio-
logical events, there is little evidence on the contribution of
these pathways to osteoblast di¡erentiation. Here we found
that BMP-2 activates both p38 MAPK and PI3K cascade in
C2C12 cells. Moreover, we have shown that inhibition of
PI3K/p70 S6K and p38 MAPK, two cascades that participate
in skeletal muscle and chondrocyte di¡erentiation, are not
required on the osteoblastic di¡erentiation program induced
by BMP-2. Finally, repression of these cascades potentiates
the e¡ect of BMP-2 inducing two late markers of osteoblast
di¡erentiation, alkaline phosphatase and osteocalcin.
Activation of p38 MAPK by BMP-2 has also been observed
in PC12 cells during neuronal di¡erentiation [28], in the
mouse chondrogenic cell line ATDC5 [29] and in mouse hy-
bridoma HM60 cells [30]. This early stimulation of p38 is
required for some transcriptional responses to TGFL super-
family members [28,31,32]. These e¡ects might be related to
the activation of TAK1, a MAPKKK member that was re-
ported to be activated as soon as 15 min after TGFL or BMP-
2 addition, and which provides a link between signalling by
TGFL superfamily members and JNK and p38 MAPK acti-
vation [33,34]. In contrast, no direct e¡ect of BMP-2 on the
PI3K/p70 S6K cascade has been described. The latency ob-
served for the BMP-2 e¡ect on this cascade by us and others
[35] suggests an indirect e¡ect of BMP-2 signalling that could
be mediated by activation of a regulatory intracellular net-
work or by release of an unknown autocrine factor.
In contrast to the stimulatory e¡ect of BMP-2 on p38
MAPK and PI3K/p70 S6K activities, blockage of these signals
by speci¢c inhibitors does not a¡ect the BMP-2-dependent
induction of the osteoblast phenotype. Surprisingly, the lack
of requirement of p38 MAPK and PI3K/p70 S6K for osteo-
genesis contrasts with their e¡ects on other mesenchymal dif-
ferentiation programs, such as myogenesis or chondrogenesis.
Indeed, inhibition of p38 MAPK blocks chondrogenesis in
micromass cultures of mesenchymal cells or in the ATDC5
chondrogenic cell line [29,36], and also inhibits myogenesis
and myoblast fusion of C2C12 or L8 cells [14,37]. It has
also been shown that inhibition of PI3K blocks myogenic
di¡erentiation [13,38] and that the PI3K-downstream kinase
Akt participates in this promyogenic e¡ect [39,40]. Both sig-
naling cascades, p38 MAPK and PI3K, seem to be independ-
ent but necessary for the ¢nal muscle phenotype [41]. Con-
¢rming all these data, SB203580, Ly294002 and rapamycin all
blocked myogenic di¡erentiation in our culture of C2C12 cells
after growth factor depletion (Fig. 2). However, at the same
dose which completely inhibits their speci¢c activities, these
inhibitors not only failed to block BMP-2-induced increases in
Cbfa1 expression and transcriptional activity but even poten-
tiated the expression of late di¡erentiation markers. A direct
inhibitory e¡ect of the p38 MAPK or PI3K/p70 S6K on
BMP-2 signalling pathway is unlikely, since addition of spe-
ci¢c inhibitors did not alter BMP-2-induced signaling or tran-
scriptional responses, and inhibition of p38 MAPK blocks
neuronal or chondrogenic di¡erentiation programs induced
by BMPs [28,29].
Previous evidence supports the hypothesis that other sig-
nals, apart from Cbfa1, are necessary to ¢nal osteoblast di¡er-
entiation, and that they would be targets of negative regula-
tion by p38 MAPK and PI3K/p70 S6K. For instance, the
same e¡ect has been shown in rat osteoblast-like osteosarco-
ma (ROS 17/2.8) cells, where rapamycin alone induces osteo-
Fig. 6. PI3K, p70 S6K or p38 MAPK inhibition does not block os-
teocalcin mRNA. A: Con£uent C2C12 cells were depleted of
growth factors and incubated in a medium containing 2% horse se-
rum for 6 days in the absence (2%) or the presence of 2 nM BMP-
2, 15 WM Ly294002 (Ly), 10 nM rapamycin (R) or 15 WM
SB203580 (SB). After this time total RNA was obtained from the
di¡erent experimental conditions and 20 Wg was load on gels. After
blotting, osteocalcin and GAPDH were detected by hybridization
using speci¢c probes. A representative autoradiogram is shown.
B: Quanti¢cation of data shown in (A). Results were normalized by
the level of GAPDH. Values represent the mean of two independent
experiments and are expressed relative to their respective BMP-2-in-
duced e¡ect.
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calcin expression and alkaline phosphatase activity, and syn-
ergizes with 1,25(OH)2D3 to induce osteoblast di¡erentiation
[42]. In addition, whereas Cbfa1 seems to play a key role in
osteoblast determination of mesenchymal cells, expression of
this transcription factor alone fails to induce the ¢nal osteo-
blast phenotype (osteocalcin or alkaline phosphatase activity)
[4]. This ability of di¡erent MAPK pathways to switch the
fate of a pluripotent mesenchymal cell population has also
been observed after inhibition of p42/p44 MAPK cascade,
switching from osteogenesis to adipogenesis [19]. These data
indicate that commitment to a mesenchymal di¡erentiation
program depends not only on the expression of known tran-
scriptional ‘master’ genes but also on a delicate equilibrium
between di¡erent signaling cascades.
Di¡erent types of cellular stress, such as mechanical loading
and hyperosmolarity generated by calci¢cation of bone extra-
cellular matrix, cause osteoblasts and osteoclasts to induce
bone remodeling. This type of stimulus has been shown to
activate p38 MAPK, inhibit p70 S6K [16,43] and to in£uence
bone remodeling and matrix deposition both in organ cultures
and in vivo [44,45]. In addition, the use of immunosuppres-
sants after organ transplantation, such as cyclosporin A or
FK-506, leads to osteoporosis, whereas rapamycin is bone-
sparing [46]. In this respect, inhibition of either p38 MAPK
or PI3K/p70S6K blocks the di¡erentiation and function of
osteoclasts [47^49] whereas in this study we found that they
potentiate the osteoblast function. Taken together, these lines
of evidence suggest a crucial role of p38 MAPK and PI3K/
p70S6K in balancing the di¡erentiation and function of both
the osteoblast and osteoclast lineages, which is relevant to our
understanding of the mechanisms of bone remodeling.
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